ACAD vs SGE.L
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative treatments for central nervous system and rare disease indications. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | ACAD | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $29.50 | £10.86 | |
| Market cap as of 2026-08-24 | $5.1B | $13.3B | |
| P/E as of 2026-08-24 | 12.85 | n/a | |
| PEG as of 2026-08-24 | 2.28 | n/a | |
| Net margin as of 2026-08-24 | +33.4% | n/a | |
| Gross margin as of 2026-08-24 | +91.1% | n/a | |
| Operating margin as of 2026-08-24 | +7.6% | n/a | |
| ROE as of 2026-08-24 | +32.4% | n/a | |
| ROA as of 2026-08-24 | +24.4% | n/a | |
| Debt / equity as of 2026-08-24 | 0.00 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +47.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.5% | n/a | |
| Beta as of 2026-08-24 | 0.86 | n/a | |
| 1-year return as of 2026-08-21 close | +19.0% | -2.5% | ACAD higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.